Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
MannKind Corporation is a biotechnology business based in the US. MannKind Corporation shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. MannKind Corporation employs 232 staff and has a trailing 12-month revenue of around USD$62.7 million.
|Latest market close||USD$2.95|
|52-week range||USD$0.8 - USD$3.2|
|50-day moving average||USD$2.3562|
|200-day moving average||USD$1.8507|
|Wall St. target price||USD$3.1|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.354|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||2.95|
|1 month (2020-11-06)||29.39%|
|3 months (2020-09-04)||79.88%|
|6 months (2020-06-05)||110.71%|
|1 year (2019-12-05)||147.90%|
|2 years (2018-12-04)||70.52%|
|3 years (2017-12-05)||-1.99%|
|5 years (2015-12-04)||52.85%|
|Revenue TTM||USD$62.7 million|
|Gross profit TTM||USD$35.1 million|
|Return on assets TTM||-17.72%|
|Return on equity TTM||0%|
|Market capitalisation||USD$693.2 million|
TTM: trailing 12 months
There are currently 21.7 million MannKind Corporation shares held short by investors – that's known as MannKind Corporation's "short interest". This figure is 14.6% down from 25.4 million last month.
There are a few different ways that this level of interest in shorting MannKind Corporation shares can be evaluated.
MannKind Corporation's "short interest ratio" (SIR) is the quantity of MannKind Corporation shares currently shorted divided by the average quantity of MannKind Corporation shares traded daily (recently around 3.2 million). MannKind Corporation's SIR currently stands at 6.78. In other words for every 100,000 MannKind Corporation shares traded daily on the market, roughly 6780 shares are currently held short.
However MannKind Corporation's short interest can also be evaluated against the total number of MannKind Corporation shares, or, against the total number of tradable MannKind Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MannKind Corporation's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 MannKind Corporation shares in existence, roughly 90 shares are currently held short) or 0.094% of the tradable shares (for every 100,000 tradable MannKind Corporation shares, roughly 94 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against MannKind Corporation.
Find out more about how you can short MannKind Corporation stock.
We're not expecting MannKind Corporation to pay a dividend over the next 12 months.
MannKind Corporation's shares were split on a 1:5 basis on 3 March 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind Corporation shares which in turn could have impacted MannKind Corporation's share price.
Over the last 12 months, MannKind Corporation's shares have ranged in value from as little as $0.8 up to $3.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind Corporation's is 2.1048. This would suggest that MannKind Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.